MEDIA

Press Releases

Select Year

14

August

2023

Revance’s Botox rival gets FDA approval for painful neck muscle condition

14

August

2023

Revance touts first therapeutic indication for Botox rival Daxxify in cervical dystonia

14

August

2023

Revance touts first therapeutic indication for Botox rival Daxxify in cervical dystonia

14

August

2023

Revance Wins First Daxxify Therapeutic Indication, Plans Limited Initial Rollout

14

August

2023

Revance pivots into therapeutics with cervical dystonia nod for Botox rival Daxxify

14

August

2023

U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia